Latest Breaking News On - Global society of rare genitourinary tumors - Page 1 : comparemela.com

Immunotherapy May Aid Certain Penile Cancer Patients: Study

Immunotherapy May Aid Certain Penile Cancer Patients: Study
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Tonik choueiriTalal el zarifYale cancer centerDana farber cancer instituteDana farber cancer institute authorsJournal of the national cancer instituteGlobal society of rare genitourinary tumorsStudy titleGlobal societyRare genitourinaryNational cancerFarber cancer institute authors

Study shows immunotherapy may benefit a subset of patients with penile cancer

Study shows immunotherapy may benefit a subset of patients with penile cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Talal el zarifGlobal society of rare genitourinary tumorsDana farber cancer instituteJournal of the national cancer instituteYale cancer centerNational cancer instituteGlobal societyRare genitourinary tumors

Testicular, Penile, and Rare GU Malignancies

Testicular, Penile, and Rare GU Malignancies Interviews with Experts at Conferences Curated by clinicians: educational forums with videos, abstracts and conference information Videos April 27, 2021 The State-of-the-Evidence in Brief Reviews by Experts May 17, 2021 Penile cancer (PC) is a rare malignancy with an incidence estimated less than 1/100 000 per year in the Western World 1-3 Historically, demolitive surgical approaches, such as total or partial penile amputation, were the most commonly used. Indeed, demolitive options were deemed to be necessary in order to respect a macroscopic surgical margin of at least 2 cm. 3-4 If the oncological outcomes of these approaches demonstrated to be satisfactory, they significantly affected aesthetic outcomes, as well as sexual and urinary functions.

United statesNew zealandJulien van dammePilar lagunaChristopher jd wallisFallen jamesZachary klaassenPhilippe spiessDarren feldmanAndrea necchiLucia nappiPhilippee spiessLyndal mooreJames lynamSilke gillessenPeter albers

GSRGT 2020: The International Germ Cell Cancer Collaborative Group (IGCCCG) Update

GSRGT 2020: The International Germ Cell Cancer Collaborative Group (IGCCCG) Update (Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12 th focused on testis cancer. In this session, the organizers convened a “Clinical Trials Corner” in which Dr. Silke Gillessen presented an update from the International Germ Cell Cancer Collaborative Group (IGCCCG). As clinicians treating germ cell tumors will know, the International Germ Cell Cancer Collaborative Group published a consensus-based prognostic classification of germ cell tumors in 1997. This stratification has been widely used since that time for both clinical care and trial design. Notably, it was based on treatments delivered between 1975 and 1990, in which not all patients received cisplatin-based regimes which would now be considered standard of care.

United statesVanderbilt universityChristopher jd wallisSilke gillessenOncology institute of southern switzerlandGlobal society of rare genitourinary tumorsHead of the department medical oncologyVanderbilt university medical centerInternational germ cell cancer collaborative groupDepartment of oncologyGlobal societyRare genitourinary tumorsProfessor silke gillessenMedical oncologistOncology instituteSouthern switzerland

GSRGT 2020: The Global Voice of Penile Cancer Research: The International Registry

GSRGT 2020: The Global Voice of Penile Cancer Research: The International Registry (UroToday.com) The Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit included an update on the international registry for penile cancer provided by Dr. Marco Bandini from San Raffaele Hospital in Milan, Italy. According to Dr. Bandini, there are several important questions under consideration, including: Is penile cancer research moving along with the incidence of the disease? Are there countries with remarkable numbers of patients with penile cancer adequately involved in multi-institutional studies? Are there open randomized clinical trials in areas where the incidence of the disease is maximal?

United statesZachary klaassenMarco bandiniGlobal society of rare genitourinary tumorsScientific instituteGeorgia cancer centerAugusta university medical college of georgiaGlobal societyRare genitourinary tumorsSan raffaele hospitalAssistant professorMedical collegeRare genitourinary tumors virtual summitஒன்றுபட்டது மாநிலங்களில்சக்கரி க்லாஸ்சேங்மார்கோ பந்தினி